+Vote!
Red Orbit (Free subscription) | 07/31/2008
"During the second quarter, we continued to make excellent progress in our Phase 3 trials of Albuferon(R) in chronic hepatitis C and LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Our timelines to Phase 3 results and the filing of marketing applications are on track for both of these key lead products. Our oncology...
+Vote!
PR News Wire (Free subscription) | 07/30/2008
... of Albuferon(R) in chronic hepatitis C and
LymphoStat-B(R) in systemic lupus erythematosus," said H. Thomas Watkins,
President and Chief Executive Officer, HGS. "Our timelines to Phase 3
results and the filing of marketing applications are on track for both of
these key lead products. Our oncology program also continued to show solid
progress. For HGS-ETR1, we expect to have data...
+Vote!
PR News Wire (Free subscription) | 07/24/2008
... accomplishment to HGS in financial strategy, planning and
business development," said H. Thomas Watkins, President and Chief
Executive Officer, HGS. "We look forward to benefiting from David's
experience and insight as we continue our transformation into a fully
commercial biopharmaceutical company. We are pleased to welcome him to our
Board."
During his fourteen-year tenure at...
